A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation
Year: 2018
Type: article
Abstract: BACKGROUND: Cerebrospinal fluid (CSF) neurofilament light (NfL) is a reliable marker of neuro-axonal damage in different neurological disorders that is related to disease severity. To date, all recent studies performed in human CSF have used the same enzyme-linked immunosorbent assay (ELISA). To confirm the large body of evidence for NfL, we developed a new ELISA method and here we present the performance characteristics of this new ELISA for CSF NfL in different neurological disorders. METHODS: We produced two monoclonal antibodies (NfL21 and NfL23) directed against the NfL core domain, and developed a novel sandwich ELISA method that we evaluated in patients with: 1) inflammatory demyelinating diseases (IDD; n = 97), including multiple sclerosis (MS; n = 59), clinically isolated syndrome (CIS; n = 32), and radiologically isolated syndrome (RIS; n = 6); 2) Alzheimer's disease (AD; n = 72), including mild cognitive impairment due to AD (MCI-AD, n = 36) and probable AD dementia (AD-dem; n = 36); 3) Parkinson's disease (PD; n = 30); and 4) other neurological noninflammatory and non-neurodegenerative diseases (OND; n = 30). RESULTS: Our new NfL ELISA showed a good analytical performance (inter-plate coefficient of variation (CV) < 13%), with no cross-reactivity with neurofilament medium and heavy (NfM and NfH). With respect to the other available ELISAs, CSF NfL showed the same range of values with a strong correlation (r = 0.9984, p < 0.001) between the two methods. CSF NfL levels were significantly higher in MCI-AD/AD-dem and IDD patients as compared with both PD and OND patients. The highest discriminative power was obtained between IDD and OND patients (area under the curve (AUC) 0.87, 95% confidence interval (CI) 0.80-0.95). Within the IDD group, CSF NfL positively correlated with several clinical and radiological disease severity parameters. CONCLUSIONS: These results show a good analytical performance of the new ELISA for quantification of NfL concentrations in the CSF. CSF NfL is confirmed to be a reliable marker in AD and MS, and a disease-severity marker in MS patients.
Source: Alzheimer s Research & Therapy
Institutions: University of Perugia, Azienda Ospedaliera di Perugia, Sahlgrenska University Hospital, University of Gothenburg, Fondazione Santa Lucia, UK Dementia Research Institute, National Hospital for Neurology and Neurosurgery, UCL Queen Square Institute of Neurology, University College London
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: neurofilament light chain, cerebrospinal fluid biomarkers, sandwich ELISA, monoclonal antibodies, multiple sclerosis, clinically isolated syndrome, radiologically isolated syndrome, inflammatory demyelinating diseases, Alzheimer's disease, mild cognitive impairment, Parkinson's disease, disease severity, analytical method validation, method comparison
Open Access status: gold
Estimated APC paid: $4,290
Funders: Torsten Söderbergs Stiftelse, Knut och Alice Wallenbergs Stiftelse, Vetenskapsrådet, Sahlgrenska Universitetssjukhuset, Göteborgs Universitet, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Alzheimerfonden, Università degli Studi di Perugia, European Research Council, Sahlgrenska Akademin
OpenAlex ID: W2787848674
